Deer­field-backed biotech emerges from stealth with gene ther­a­py de­liv­ery plat­forms from Har­vard and MIT

As a PhD stu­dent at Tufts, Dave Green­wald stud­ied the use of ade­no-as­so­ci­at­ed virus (AAV) vec­tors to de­liv­er gene ther­a­pies to peo­ple with re­tini­tis pig­men­tosa, a group of rare ge­net­ic eye dis­eases that caus­es the reti­na to break down over time.

While he lat­er left lab life, he now sits at the helm of Aper­tu­ra Gene Ther­a­py, a biotech that hopes to cus­tomize AAV vec­tors that are used wide­ly in de­liv­er­ing most gene ther­a­pies. Aper­tu­ra an­nounced its launch from stealth with $67 mil­lion in Se­ries A fi­nanc­ing from Deer­field, where Green­wald is al­so a vice pres­i­dent of busi­ness de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER